(MED) MEDIFAST - Ratings and Ratios

Medifast, Inc. (NYSE:MED) is a health and wellness company specializing in habit-based and coach-guided lifestyle solutions to combat obesity and promote sustainable weight management. Founded in 1980 and headquartered in Baltimore, Maryland, the company operates primarily in the United States under the OPTAVIA brand. Its product portfolio includes weight loss and weight management plans, as well as GLP-1 receptor agonist support programs, which integrate clinically appropriate medications with lifestyle interventions. Medifast offers a range of nutritionally formulated products, including bars, shakes, soups, and snacks, designed to support adherence to its structured programs. These offerings are complemented by personalized coaching and community support to help individuals maintain healthy habits. The company distributes its products through both point-of-sale transactions and its e-commerce platform, catering to a growing demand for holistic wellness solutions in the personal care products sector.

Looking ahead, Medifasts stock (NYSE:MED) is expected to face headwinds in the next three months based on current technical and fundamental trends. Technically, the stock is trading below its 20-day, 50-day, and 200-day moving averages, signaling bearish momentum. The average true range (ATR) of 0.72 suggests moderate volatility, which could lead to price swings in response to earnings or macroeconomic developments. On the fundamental side, while the companys market cap of $157.07M reflects its established presence, the trailing P/E ratio of 75.58 indicates a premium valuation relative to earnings. The forward P/E is currently undefined, which may signal uncertainty about future profitability. However, the price-to-sales (P/S) ratio of 0.26 suggests the stock may be undervalued relative to its revenue generation. Overall, the next quarter will likely hinge on Medifasts ability to demonstrate revenue growth and margin expansion to justify its current valuation.